Scottsdale, AZ – September 24, 2019 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, is pleased to announce the appointment of Dr. Frank Gerberick to its Board of Advisors to help advance the Company’s SkinGun™ cell spray technology for the regeneration of human skin.
Today’s news follows last month’s appointment of RenovaCare Vice-President of Scientific Affairs, Dr. Robin Robinson, founding director of BARDA and cited in 2018 as one of the top 100 innovators in medicine by The Medicine Maker. Just prior, the USPTO awarded a new patent to RenovaCare, allowing its SkinGun™ to spray all varieties of tissues and cells, and thus opening the door for its potential application in regenerative applications beyond skin.
Recent breakthroughs in stem cell therapies include the regeneration of human organs, tissues and bone. RenovaCare believes that the ultra-gentle spray-on application of such cells could be investigated and developed by way of commercial collaborations and partnerships.
Following the completion of his postdoctoral fellowship at The Johns Hopkins University School of Medicine, Dr. Gerberick commenced a long-spanning career at Procter & Gamble. Dr. Gerberick was appointed to the Procter & Gamble’s Victor Mills Society, the highest technical honor for P&G scientists. At P&G, he focused his research career in the areas of dermatotoxicology, immunotoxicology and phototoxicology.
“My career has been focused around product safety – specifically around contact dermatitis. The proven rapid-healing and therapeutic benefits of the RenovaCare SkinGun™ and CellMist™ solution through use of a person’s own stem cells is an exciting, cutting-edge technology to study. One of the key areas of bringing a medical device to market is mitigating adverse events such as the occurrence of skin allergy. I look forward to working with the RenovaCare team and sharing with them my expertise in these areas in order to bring this much needed therapy to market,” stated Dr. Frank Gerberick, RenovaCare Advisory Board Member.
Trained in immunology and microbiology with thirty-one years of experience, Dr. Gerberick is the recipient of several prestigious awards related to his development of alternative models and approaches for conducting skin allergy risk assessments. Dr. Gerberick was also selected as an Alexander A. Fisher Lecturer, the highest honor given by the American Contact Dermatitis Society.
While at Procter & Gamble, his laboratory’s research was focused primarily on elucidating the chemical, cellular and molecular mechanisms underlying skin allergy in hope of developing in vitro test methods for skin sensitization testing. In the past, his laboratory was actively involved in the development and validation of the LLNA. For his effort, he was a co-recipient of two prestigious international awards: the SmithKline Beecham Laboratory Animal Welfare Prize and the Society of Toxicology’s Animal Welfare Award.
He was also awarded the William and Elenor Cave Award and Lush Black Box Prize for advancing skin sensitization alternatives. The Direct Peptide Reactivity Assay developed in Dr. Gerberick’s laboratory has been successfully evaluated by the European Union Reference Laboratory for Alternatives to Animal Testing and adopted as OECD test guideline.
Dr. Gerberick has authored over 175 publications and co-authored a book entitled Toxicology of Contact Dermatitis..
Spraying Skin Stem Cells onto Burns and Wounds
To date, over 70 patients with various types of second-degree burns have been treated on an experimental basis utilizing the technology underlying the Company’s SkinGun™, which RenovaCare has developed as a potential alternative to skin grafting and other treatment options, such as in-vitro cultured epithelial grafts that require a specialized and expensive external laboratory.
Sprayed with a gentle mist of their own skin cells, many of these patients left the hospital within days, avoiding generally painful skin graft surgeries and potentially weeks of hospitalization. Clinical outcomes of early experimental treatments have been peer-reviewed and published in several medical journals, including Burns and Annals of Plastic Surgery.
Patients who undergo skin grafting, today’s default treatment of care, can remain hospitalized for weeks and even months, and often enduring painful and costly surgeries and prolonged physical therapy. Some of these patients may also suffer from the psychological effects of disfigurement caused by permanent scarring and often cope with the ongoing use of pain medications and protracted joint mobility issues.
RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.
RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds.
RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
For additional information, please call Amit Singh at: 888-398-0202 or visit: http://renovacareinc.com
To receive future press releases via email, please visit: http://renovacareinc.com/investors/register/
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:
* This list may be updated from time to time.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company’s technologies, technical problems with the Company’s research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.